Insights

Expanding Leadership The recent appointment of new CEO James Cheek indicates a strategic shift and potential growth focus, presenting opportunities to engage with leadership for partnership or sales initiatives aimed at expanding market reach.

Innovative Products Genedrive's development of rapid pharmacogenetic kits like the MT-RNR1 and CYP2C19 positions it well to capitalize on increasing demand for personalized medicine and point-of-care testing solutions, especially in emergency and critical care settings.

Market Penetration The company's recent regulatory approvals and collaborations with NHS partners suggest a strong foothold in the UK healthcare system, opening avenues to expand into other regions with similar regulatory pathways and healthcare infrastructure.

COVID-19 Portfolio Genedrive's previous success with SARS-CoV-2 testing indicates a proven capability to develop and distribute rapid diagnostic solutions, which could be leveraged to explore additional infectious disease testing markets or expand existing product lines.

Potential Growth Although current revenues are modest, ongoing product development and strategic hires suggest the company is positioning itself for growth, making it an attractive partner for investors or collaborators interested in advancing point-of-care diagnostics.

Similar companies to genedrive

genedrive Tech Stack

genedrive uses 8 technology products and services including ISO 13485, Cookie Notice, Google Fonts API, and more. Explore genedrive's tech stack below.

  • ISO 13485
    Certificates
  • Cookie Notice
    Cookie Compliance
  • Google Fonts API
    Font Scripts
  • JSON-LD
    Javascript Frameworks
  • Swiper
    Javascript Libraries
  • Google Tag Manager
    Tag Management
  • Google Analytics
    Web Analytics
  • MonsterInsights
    Web Platform Extensions

Media & News

genedrive's Email Address Formats

genedrive uses at least 2 format(s):
genedrive Email FormatsExamplePercentage
FLast@genedriveplc.comJDoe@genedriveplc.com
50%
F.Last@genedriveplc.comJ.Doe@genedriveplc.com
20%
First@genedriveplc.comJohn@genedriveplc.com
12%
FirstLast@genedriveplc.comJohnDoe@genedriveplc.com
8%
Last@genedriveplc.comDoe@genedriveplc.com
4%
First-Last@genedriveplc.comJohn-Doe@genedriveplc.com
2%
First.Last@genedriveplc.comJohn.Doe@genedriveplc.com
2%
First_Last@genedriveplc.comJohn_Doe@genedriveplc.com
2%
F.Last@genedrive.comJ.Doe@genedrive.com
100%

Frequently Asked Questions

What is genedrive's stock symbol?

Minus sign iconPlus sign icon
genedrive is a publicly traded company; the company's stock symbol is GDR.L.

What is genedrive's official website and social media links?

Minus sign iconPlus sign icon
genedrive's official website is genedrive.com and has social profiles on LinkedInCrunchbase.

What is genedrive's NAICS code?

Minus sign iconPlus sign icon
genedrive's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does genedrive have currently?

Minus sign iconPlus sign icon
As of December 2025, genedrive has approximately 46 employees across 1 continents, including Europe. Key team members include Ceo: G. M.Chief Commercial Officer: P. B.Operations Director: J. B.. Explore genedrive's employee directory with LeadIQ.

What industry does genedrive belong to?

Minus sign iconPlus sign icon
genedrive operates in the Medical Equipment Manufacturing industry.

What technology does genedrive use?

Minus sign iconPlus sign icon
genedrive's tech stack includes ISO 13485Cookie NoticeGoogle Fonts APIJSON-LDSwiperGoogle Tag ManagerGoogle AnalyticsMonsterInsights.

What is genedrive's email format?

Minus sign iconPlus sign icon
genedrive's email format typically follows the pattern of FLast@genedriveplc.com. Find more genedrive email formats with LeadIQ.

When was genedrive founded?

Minus sign iconPlus sign icon
genedrive was founded in 2016.

genedrive

Medical Equipment ManufacturingEngland, United Kingdom11-50 Employees

Genedrive Diagnostics Ltd is a pharmacogenetic testing company developing and commercialising a rapid and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners.

The Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway.

The Genedrive® CYP2C19 ID Kit empowers clinicians to make informed treatment decisions for stroke patients based on their individual ability to metabolise the antiplatelet clopidogrel.

Section iconCompany Overview

Stock Symbol
GDR.L
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2016
Employees
11-50

Section iconFunding & Financials

  • $1M

    genedrive's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $1M

    genedrive's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.